A New York proposal could redraw the economics of home delivery. Manus is on its own again after the Meta deal. Edison scores ...

RadNet's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. Read why ...

Intel executed a massive equity offering, raising $20–$23 billion by selling over 240 million shares at $95 each. Read why ...

The Cboe Volatility Index averaged 19.0 across the first seven months of 2026 and closed below 20 on 110 of 148 sessions. Implied volatility on the S&P 500 exceeded trailing 21-day realized volatility ...

Rocket Lab Corporation is nearing a major inflection point, targeting profitability in eFY27, driven by Neutron launches and the pending Iridium acquisition. RKLB’s backlog has grown to $2.36b with ...

A large part of constructing a retirement portfolio is understanding what you are investing in. Different investments have different return profiles. Some companies don't pay any dividends at all; ...

Legend Biotech is transitioning from a capital-intensive biotech to a profitable, CARVYKTI-driven commercial cell therapy company. Q2 results highlight 52% YoY revenue growth, strong international ...

Hims & Hers Health delivered strong Q2 2026 revenue growth but suffered margin compression and negative free cash flow. I rate HIMS a Sell, as the raised revenue guidance is offset by declining gross ...

Performance Food Group Company (PFGC) fell in early action on Wednesday after slightly missing consensus estimates with its fiscal fourth quarter earnings report. Net sales for the quarter were up 6.4 ...

AI-driven capabilities on the legacy hardware/software offerings and the prior inventory buildout have boosted AXON's contracted bookings metric. The razor-and-blade model drives hardware adoption, ...

The last time I spoke about Protagonist Therapeutics (PTGX) it was with a Seeking Alpha article entitled as "Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It." With respect to ...

Tutor Perini is not threatened by AI agents; AI will enhance design and documentation efficiency. Significant 2025 share-based compensation expense was a one-off due to legacy awards and a sharp stock ...